Literature DB >> 27147632

Profound opiate toxicity in gastroparesis following therapeutic dose.

Henry Craven1, Hina Iftikhar2, Pallav Bhatnagar1.   

Abstract

Gastroparesis is defined by the presence of delayed gastric emptying without mechanical obstruction. Patients may present with severe discomfort that can mimic an acute abdomen including abdominal pain, vomiting, nausea, bloating, fullness and early satiety. The prevalence of gastroparesis is estimated at 24 per 100 000 and women are more commonly affected than men. It is associated with a number of conditions including diabetes, Parkinson's disease, multiple sclerosis, previous abdominal surgeries and connective tissue disorders, including scleroderma and Ehlers-Danlos syndrome. Drugs known to prolong gastric transit time, such as opiates, have been shown to exacerbate symptoms. We report a case of a 20-year-old woman with Ehlers-Danlos syndrome who developed respiratory depression after being administered a therapeutic dose of morphine. This occurred due to opiate toxicity confounded by gastroparesis. The patient required further support from intensive care until she recovered, and eventually underwent a gastric pacing procedure for symptomatic relief. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27147632      PMCID: PMC4885361          DOI: 10.1136/bcr-2016-215308

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  4 in total

Review 1.  American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis.

Authors:  Henry P Parkman; William L Hasler; Robert S Fisher
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

2.  Factors related to abdominal pain in gastroparesis: contrast to patients with predominant nausea and vomiting.

Authors:  W L Hasler; L A Wilson; H P Parkman; K L Koch; T L Abell; L Nguyen; P J Pasricha; W J Snape; R W McCallum; I Sarosiek; G Farrugia; J Calles; L Lee; J Tonascia; A Unalp-Arida; F Hamilton
Journal:  Neurogastroenterol Motil       Date:  2013-02-17       Impact factor: 3.598

3.  Demography, clinical characteristics, psychological and abuse profiles, treatment, and long-term follow-up of patients with gastroparesis.

Authors:  I Soykan; B Sivri; I Sarosiek; B Kiernan; R W McCallum
Journal:  Dig Dis Sci       Date:  1998-11       Impact factor: 3.199

4.  Neuroenteric Stimulation for Gastroparesis.

Authors:  Brian E Lacy
Journal:  Curr Treat Options Gastroenterol       Date:  2015-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.